What is Scopio?
Scopio is at the forefront of revolutionizing cell morphology analysis through a comprehensive suite of fully digital diagnostic applications and platforms. The company addresses a critical tradeoff between field-of-view and resolution, enabling laboratories to assess and analyze cell morphology at unprecedented scale and depth. By integrating high-resolution imaging with an AI-powered decision support system, Scopio enhances the efficiency and consistency of the diagnostic process across the continuum of care. Its FDA-cleared and CE-marked Full-Field Peripheral Blood Smear application, alongside its ScopioVet veterinary application, are already in commercial use in the U.S. and Europe, demonstrating the company's market traction and technological validation.
How much funding has Scopio raised?
Scopio has raised a total of $118M across 3 funding rounds:
Series B
$16M
Series C
$50M
Series D
$52M
Series B (2020): $16M with participation from Aurum Ventures Private, LR group, Olive Tree Ventures, and OurCrowd
Series C (2022): $50M led by Ilex Medical, OurCrowd, Bank Mizrahi-Tefahot, and Aurum
Series D (2025): $52M supported by Viola Group and Fortissimo
Key Investors in Scopio
Viola Group
Viola Group is a leading technology investment firm in Israel, managing substantial assets and supporting the growth of transformational technology companies. Their multi-strategy approach, encompassing venture capital, growth equity, and credit, targets companies across various development stages, particularly in technology and FinTech.
Fortissimo
Fortissimo Capital is an Israeli private equity fund specializing in technology and industrial companies, employing a proactive strategy for sustainable growth. They focus on providing capital for special situations, buyouts, and growth opportunities, targeting companies with strong revenue and growth potential.
Ilex Medical
Ilex Medical is a long-standing provider of medical instrumentation and diagnostic solutions, committed to advancing public health through innovative technologies. With decades of experience, the company offers a range of solutions in areas like microbiology and laboratory automation, serving healthcare providers.
What's next for Scopio?
With substantial backing and a clear trajectory of growth, Scopio is poised for accelerated expansion. The recent major strategic investment signals confidence from its investors in the company's innovative approach to medical diagnostics. This capital will likely fuel further research and development, enhance its AI capabilities, and broaden its commercial reach into new markets. Scopio's focus on improving diagnostic accuracy and speed positions it as a key player in the digital health and medical imaging sectors, with potential for significant impact on patient outcomes and healthcare efficiency.
See full Scopio company page
